AR074628A1 - PIRIDINE DERIVATIVES 2- AMINO-6-RENT SUBSTITUTES USEFUL AS INHIBITORS OF P2Y12 308 - Google Patents

PIRIDINE DERIVATIVES 2- AMINO-6-RENT SUBSTITUTES USEFUL AS INHIBITORS OF P2Y12 308

Info

Publication number
AR074628A1
AR074628A1 ARP090102522A ARP090102522A AR074628A1 AR 074628 A1 AR074628 A1 AR 074628A1 AR P090102522 A ARP090102522 A AR P090102522A AR P090102522 A ARP090102522 A AR P090102522A AR 074628 A1 AR074628 A1 AR 074628A1
Authority
AR
Argentina
Prior art keywords
ring
alkyl
heterocyclyl
cycloalkyl
aryl
Prior art date
Application number
ARP090102522A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR074628A1 publication Critical patent/AR074628A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere con los procesos para preparar tales compuestos, con su utilidad como inhibidores de P2Y12 y como agentes antitrombóticos, etc., con su uso como medicamentos en las enfermedades cardiovasculares así como con las composiciones farmacéuticas que los contienen. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo, donde R1 representa R7C(O); R2 representa alquil C1-3 insustituido; R7 representa alquil C1-6 opcionalmente interrumpido por oxígeno, y/u opcionalmente sustituido por OH, aril, cicloalquil C3-6, heterociclil o uno o más átomos de halógeno (F, Cl, Br o I); además R7 representa cicloalquil C3-6, hidroxi-alquil C1-6, aril o heterociclil; B es un sistema de anillos/anillo monocíclico, bicíclico o heterocíclico de 4 a 11 miembros que comprende uno o más nitrógenos y opcionalmente uno o más átomos seleccionados de oxígeno o azufre, dicho nitrógeno está unido al anillo de piridina (de acuerdo con la fórmula (1)) y además el sistema de anillos/anillo B está unido a X en otra de sus posiciones; el sustituyente R14 está unido al sistema de anillos/anillo B de tal manera que no se forma ningún compuesto de amonio cuaternario (por esta unión); R14 representa H, OH con la condición de que el grupo OH debe estar al menos 2 átomos de carbono separado de cualquier heteroátomo en el sistema de anillos/anillo B, alquil C1-6 opcionalmente interrumpido por oxígeno y/u opcionalmente sustituido por uno o más OH, COOH y COORe; donde Re representa aril, cicloalquil C3-6, heterociclil o alquil C1-6 opcionalmente sustituido por uno o más átomo(s) de halógeno (F, Cl, Br o I), OH, aril, cicloalquil C3-6 y heterociclil; además R14 representa aril, aril-alquil C1-6, aril-alcoxi C1-6, heterociclil, un átomo de halógeno (F, Cl, Br o I), cicloalquil C3-6, cicloalquil C3-6-alcoxi C1-6, hidroxi-alquil C1-6, alcoxi C1-6, cicloalcoxi C3-6, alquilsulfinil C1-6, alquilsulfonil C1-6, alquiltio C1-6, cicloalquiltio C3-6, o un grupo de la fórmula NRa(14)Rb(14) en la cual Ra(14) y Rb(14) independientemente representan H, alquil C1-6, alquil C1-6C(O), alcoxi C1-6C(O) o Ra(14) y Rb(14) junto con el átomo de nitrógeno representan piperidina, pirrolidina, azetidina o aziridina; Rc es metileno (-CH2-); Rd representa fenil que tiene 0, 1, 2, 3, 4 ó 5 sustituyentes seleccionados entre halógenos o halógenos mezclados o fenil que tiene un grupo alcoxi C1-6 insustituido; X representa un enlace simple, imino (-NH-), metileno (-CH2-), iminometileno (-CH2-NH-) donde el carbono está unido al sistema de anillos/anillo B, metilenoimino (-NH-CH2-) donde el nitrógeno está unido al sistema de anillos/anillo B y cualquier carbono y/o nitrógeno en estos grupos puede opcionalmente ser sustituido con alquil C1-6; además X puede representar un grupo (-CH2-)n donde n = 2 - 6, el cual opcionalmente es insaturado y/o sustituido por uno o más sustituyentes seleccionados entre halógeno, hidroxil o alquil C1-6; el término "aril" denota un hidrocarburo aromático (C6-14) sustituido o insustituido; y el término "heterociclil" denota un sistema de anillos monocíclico o multicíclico de 4 a 10 miembros sustituido o insustituido en el cual uno o más de los átomos en el anillo o los anillos es un elemento distinto de carbono.It refers to the processes for preparing such compounds, with their usefulness as P2Y12 inhibitors and as antithrombotic agents, etc., with their use as medicaments in cardiovascular diseases as well as with the pharmaceutical compositions containing them. Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt thereof, wherein R 1 represents R 7 C (O); R2 represents unsubstituted C1-3 alkyl; R7 represents C1-6 alkyl optionally interrupted by oxygen, and / or optionally substituted by OH, aryl, C3-6 cycloalkyl, heterocyclyl or one or more halogen atoms (F, Cl, Br or I); R7 also represents C3-6 cycloalkyl, hydroxyC 1-6 alkyl, aryl or heterocyclyl; B is a 4 to 11-membered monocyclic, bicyclic or heterocyclic ring / ring system comprising one or more nitrogen and optionally one or more atoms selected from oxygen or sulfur, said nitrogen is attached to the pyridine ring (according to the formula (1)) and also the ring / ring system B is connected to X in another of its positions; substituent R14 is attached to the ring / ring B system in such a way that no quaternary ammonium compound is formed (by this bond); R14 represents H, OH with the proviso that the OH group must be at least 2 carbon atoms separated from any heteroatom in the ring / ring B system, C1-6 alkyl optionally interrupted by oxygen and / or optionally substituted by one or more OH, COOH and COORe; where Re represents aryl, C3-6 cycloalkyl, heterocyclyl or C1-6 alkyl optionally substituted by one or more halogen atom (s) (F, Cl, Br or I), OH, aryl, C3-6 cycloalkyl and heterocyclyl; R14 also represents aryl, arylC 1-6 alkyl, arylC 1-6 alkoxy, heterocyclyl, a halogen atom (F, Cl, Br or I), C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-6 alkoxy, hydroxyC 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkoxy, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, C 1-6 alkylthio, C 3-6 cycloalkylthio, or a group of the formula NRa (14) Rb (14 ) in which Ra (14) and Rb (14) independently represent H, C1-6 alkyl, C1-6C alkyl (O), C1-6C alkoxy (O) or Ra (14) and Rb (14) together with the nitrogen atom represent piperidine, pyrrolidine, azetidine or aziridine; Rc is methylene (-CH2-); Rd represents phenyl having 0, 1, 2, 3, 4 or 5 substituents selected from halogens or mixed halogens or phenyl having an unsubstituted C1-6 alkoxy group; X represents a simple bond, imino (-NH-), methylene (-CH2-), iminomethylene (-CH2-NH-) where carbon is attached to the ring / ring B system, methyleneimino (-NH-CH2-) where the nitrogen is attached to the ring / ring B system and any carbon and / or nitrogen in these groups can optionally be substituted with C1-6 alkyl; in addition X can represent a group (-CH2-) n where n = 2-6, which is optionally unsaturated and / or substituted by one or more substituents selected from halogen, hydroxyl or C1-6 alkyl; the term "aryl" denotes a substituted or unsubstituted (C6-14) aromatic hydrocarbon; and the term "heterocyclyl" denotes a substituted or unsubstituted monocyclic or multicyclic ring system of 4 to 10 members in which one or more of the atoms in the ring or rings is a non-carbon element.

ARP090102522A 2008-07-07 2009-07-06 PIRIDINE DERIVATIVES 2- AMINO-6-RENT SUBSTITUTES USEFUL AS INHIBITORS OF P2Y12 308 AR074628A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7848408P 2008-07-07 2008-07-07

Publications (1)

Publication Number Publication Date
AR074628A1 true AR074628A1 (en) 2011-02-02

Family

ID=41507302

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102522A AR074628A1 (en) 2008-07-07 2009-07-06 PIRIDINE DERIVATIVES 2- AMINO-6-RENT SUBSTITUTES USEFUL AS INHIBITORS OF P2Y12 308

Country Status (2)

Country Link
AR (1) AR074628A1 (en)
WO (1) WO2010005385A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111303146A (en) * 2018-12-11 2020-06-19 中国科学院上海药物研究所 3-cyanopyridine compound, pharmaceutical composition containing same, preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1836189A1 (en) * 2005-01-06 2007-09-26 AstraZeneca AB Novel pyridine compounds
US20080312208A1 (en) * 2005-07-13 2008-12-18 Astrazeneca Ab Pyridine Analogues
TW200815426A (en) * 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
KR20090031605A (en) * 2006-07-04 2009-03-26 아스트라제네카 아베 New pyridine analogues
WO2008004945A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline forms i and ii
WO2008004944A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline form ii
EP2041115A4 (en) * 2006-07-04 2010-07-07 Astrazeneca Ab New pyridine analogues
CL2008000092A1 (en) * 2007-01-12 2008-09-05 Astrazeneca Ab COMPOUNDS DERIVED FROM 3-CYANOPIRIDINE, INHIBITORS OF THE P2Y12 RECEPTOR; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE DISORDER OF THE PLAQUETARY AGGREGATION.

Also Published As

Publication number Publication date
WO2010005385A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
AR061651A1 (en) PIRIDINE ANALOGS II
AR084553A1 (en) HIDEROCICLIC INHIBITING IMIDAZOLIC DERIVATIVES OF b-SECRETASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME TO TREAT NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER
AR062677A1 (en) DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
CO6290658A2 (en) DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JACK INHIBITORS
AR077695A1 (en) PIRIMIDINE DERIVATIVES AS INHIBITORS OF FACTOR IXA
AR056560A1 (en) PIRROLOPIRIDINONES AS MODULATORS CB1
AR061737A1 (en) COMPOUNDS DERIVED FROM PIRIMIDINE, A BELL FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR070343A1 (en) PIRIDINIL AMIDAS, A PROCEDURE FOR THE TREATMENT OF SCHIZOPHRENIA IN A MAMMER AND A PHARMACEUTICAL COMPOSITION
CO6761320A2 (en) Bridged Piperidine Derivatives
AR074358A1 (en) PIRAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10
AR053092A1 (en) COMPOUNDS DERIVED FROM PHENOXYACETIC ACID AND INTERMEDIATE SYNTHESIS COMPOUNDS
AR087328A1 (en) IMIDAZO DERIVATIVES [1,2-B] PIRIDAZINE AND IMIDAZO [4,5-B] PIRIDINA AS JAK INHIBITORS
AR085908A1 (en) DERIVATIVES OF 3-BUTIN-2-OL AND CARBONITRILE WITH INHIBITING ACTIVITY OF THE NF-kB INDUCTING KINASE (NIK)
AR054632A1 (en) PIRIDINE ANALOGS, COMPOSITIONS THAT CONTAIN THEM AND PROCESSES FOR THEIR PREPARATION
ECSP088731A (en) DERIVATIVES OF 1,2,4,5-TETRAHIDRO-3H-BENZAZEPINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CO6241123A2 (en) MODULATORS OF THE GAMMA SECRETASA
AR047531A1 (en) DERIVATIVES 1H-TIENO (2,3-C) PIRAZOL USEFUL AS QUINASE INHIBITORS
CO6210724A2 (en) HETEROCICLIC COMPOUND AND PHARMACEUTICAL COMPOSITION OF THE SAME
AR075531A1 (en) DERIVATIVES OF PIPERAZIN-CICLOPROPIL BENZAMIDAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM, SUCH AS ALZHEIMER AND SCHIZOPHRENIA, BETWEEN OTHERS
AR077525A1 (en) 4-ARIL-BUTAN-1,3-DIAMIDES AND PHARMACEUTICAL COMPOSITIONS
AR069813A1 (en) DERIVATIVES OF 2- AMINO-PYRIMIDINE, A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARATION OF THE COMPOUND AND USE OF IT TO PREPARE A MEDICINAL PRODUCT
AR041883A1 (en) PIRIDOPIRIMIDINONE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ECSP11011196A (en) PIPERIDINE DERIVATIVES
CO6190618A2 (en) PIRIDINE COMPOUNDS AND ITS USE AS AN ANALOGONISTS OF P2 Y12
AR071587A1 (en) HETEROCICLICAL COMPOUNDS AS MEK INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure